They argued that HA-decorated nanoparticles differently inhibited the viability of cancer cells based on CD44 receptors, i.e., blocking of the CD44 receptor of HepG2 cells (a CD44 positive cell) resulted in a decrease of anticancer activity while nanoparticles did not significantly affect the death of CT26 cells (a CD44-negative cell). The gene discussed is CD44; the disease is cancer.